Nano-X Imaging Ltd. (NNOX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: a 23% revenue increase is positive, but widening losses and weak margins are concerning. The optimistic guidance for 2026 and strategic acquisition of Nanox Health IT Inc. provide potential upside. However, the lack of clear guidance on teleradiology growth and increased expenses, particularly in sales and marketing, offset these positives. The Q&A highlights management's reluctance to provide detailed forecasts, adding uncertainty. With no significant catalysts or market cap details, the stock is likely to remain neutral, fluctuating between -2% and 2% over the next two weeks.
Key Financial Performance
GAAP Net Loss $33.4 million for Q4 2025, compared to $14.1 million in Q4 2024. The increase was largely due to an impairment of long-lived assets amounting to $17.5 million as part of the company's restructuring plan, as well as increases in gross loss, sales and marketing expenses, and other expenses.
Revenue $3.7 million for Q4 2025, compared to $3.0 million in Q4 2024, representing a 23% increase. This increase was driven by a $0.3 million rise in revenue from teleradiology services and a $0.4 million contribution from the consolidation of Nanox Health IT Inc. after its acquisition.
Gross Loss $3.6 million on a GAAP basis for Q4 2025, compared to $2.9 million in Q4 2024. Non-GAAP gross loss was $1.2 million for Q4 2025, compared to $0.3 million in Q4 2024, reflecting a gross loss margin of approximately 32% on a non-GAAP basis for Q4 2025, compared to 9% in Q4 2024.
Teleradiology Services Revenue $3.1 million for Q4 2025, compared to $2.8 million in Q4 2024. The increase was attributed to customer retention, increased rates, and higher volume of reading services.
Teleradiology Services Gross Profit $0.9 million on a GAAP basis for Q4 2025, with a gross profit margin of approximately 27%, compared to $0.6 million and a margin of 21% in Q4 2024. Non-GAAP gross profit was $1.5 million for Q4 2025, with a margin of approximately 48%, compared to $1.1 million and a margin of 41% in Q4 2024.
Imaging Systems Revenue $49,000 for Q4 2025, compared to $136,000 in Q4 2024. The gross loss was $2.6 million on both GAAP and non-GAAP bases for Q4 2025, compared to $1.5 million in Q4 2024.
AI and Software Solutions Revenue $0.5 million for Q4 2025, compared to $0.1 million in Q4 2024. This includes $0.4 million generated by Nanox Health IT Inc. since its acquisition. Non-GAAP gross profit was $0.1 million for Q4 2025, compared to $6,000 in Q4 2024.
Research and Development Expenses $4.8 million for Q4 2025, compared to $5.4 million in Q4 2024, representing a decrease of $0.6 million. The decrease was due to reductions in share-based compensation, grants received, and expenses related to R&D activities, partially offset by an increase in salaries and wages.
Sales and Marketing Expenses $2.0 million for Q4 2025, compared to $0.9 million in Q4 2024, representing an increase of $1.1 million. This was mainly due to higher salaries and wages and increased expenses related to the RSNA conference.
General and Administrative Expenses $6.0 million for Q4 2025, compared to $5.8 million in Q4 2024, representing an increase of $0.2 million. The increase was mainly due to expenses related to the acquisition of Nanox Health IT Inc.
Cash, Cash Equivalents, and Marketable Securities $60 million as of December 31, 2025, compared to $55.5 million as of September 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nanox.ARC Deployment: Entered into an agreement with Howard Technology Solutions to deploy 300 Nanox.ARC systems over 3 years, with 60 systems in the first year. Additional agreements for 360 systems over 2-3 years.
Nanox Imaging Network: Initiative to build a network-based imaging services model in the U.S., targeting segments like workers' compensation and specialized care.
AI and Software Solutions: Cedars-Sinai Medical Center joined a trial for Nanox.AI aortic valve calcification measurement solution. Strategic acquisition of VasoHealthcare IT (now Nanox Health IT) to enhance integration into clinical workflows.
U.S. Market Expansion: Signed agreements with multiple distributors (e.g., Imperial Imaging, Integrity Imaging) to expand geographic coverage and strengthen distribution capabilities.
European and Latin American Expansion: Exclusive distribution agreement with Intec SRL in Argentina and collaborations in France, Romania, Czech Republic, and Serbia to navigate local regulatory environments and expand commercialization.
Korean Manufacturing Restructuring: Restructuring plan to close chip manufacturing line in South Korea, downsize facilities, and shift production to international partners like CSEM to reduce costs and improve efficiency.
Operational Efficiency: Efforts to streamline deployment processes, including addressing import licenses, construction timelines, and regulatory requirements.
Strategic Acquisitions: Acquired VasoHealthcare IT to strengthen health IT capabilities and support cross-engagement across ecosystems.
Regulatory Advancements: Advanced TAP2D clearance in the U.S. and updated AMAR approval in Israel. Working on CE Mark submission for Nanox.ARC in Europe.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Disruptions: Efforts were made to secure the supply chain due to the current geopolitical situation, indicating potential risks to operations if disruptions occur.
Regulatory and Licensing Delays: The pace of deployment is influenced by external processes such as import licenses, construction timelines, and regulatory requirements in certain markets, which could slow down operations and revenue generation.
Operational Restructuring: Restructuring activities in the Korean manufacturing facility to reduce OpEx and cash burn could pose risks during the transition period, including potential inefficiencies or delays.
Revenue Generation Challenges: The current revenue base is at an early stage, with part of the deployed systems not generating revenue. The timing of revenue ramp-up depends on system activation and utilization.
Manufacturing Transition Risks: The shift to an outsourced production model and closure of the South Korean chip manufacturing line could lead to transitional challenges and potential disruptions in production.
Economic and Financial Risks: The company reported a significant net loss for the quarter, including a $17.5 million impairment due to restructuring, which could impact financial stability.
Market Adoption Challenges: Introducing new technology into medical environments is complex and requires alignment across clinical workflows, regulatory frameworks, and operational infrastructure, potentially delaying adoption.
Geopolitical Risks: The geopolitical situation in the Middle East was noted, though no material disruptions were reported yet, indicating a potential risk to operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Target for 2026: The company continues to target $35 million in revenue for the full year of 2026 based on the execution of current plans.
System Deployments: Howard Technology Solutions is expected to deploy 300 Nanox.ARC systems over a 3-year period, with 60 systems indicated for deployment in the first year. Additionally, multiple commercial agreements could result in the placement of up to 400 systems globally over the next 2-3 years.
Revenue Growth Drivers: Revenue growth is expected to build as more systems move into operation and utilization increases. However, the timing of this trend will depend on deployment processes, system activation, and transition into revenue-generating operations.
Operational Restructuring: The company is restructuring its Korean manufacturing facility to reduce operational expenses and cash burn. Production will shift to international manufacturing partners, such as CSEM in Switzerland, to improve efficiency and align with projected demand.
Regulatory Approvals: The company is working to finalize CE Mark submission for the Nanox.ARC in Europe, anticipated in 2026, and aims to remove adjunctive-use limitations in the U.S. to expand the addressable market.
AI Business Expansion: The AI business is expected to contribute to revenue growth through new customer acquisitions, expansion of existing agreements, and integration of Nanox Health IT capabilities.
Market Engagement: Increased engagement and interest were observed at major radiology conferences (RSNA and ECR), reflecting growing awareness and potential adoption of Nanox.ARC systems.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you talk about your footprint and commercial organization in the U.S., including direct sales teams and distribution channels?
A:The company has 5 direct salespeople in the U.S., led by a Director of Sales with significant experience. They also have clinical education specialists who train personnel at installation sites and build awareness among referring physicians. Additionally, there are administrative, operational, and technical staff for installations and deal flow. They are adding 2 more people for channel management to support their 10 business partners. The onboarding process for partners is methodical, involving training and demo units.
Q:Could you provide details about the South Korean facility and the impairment? What should we expect for 2026, including restructuring and impairment timing, and whether it will be cash or noncash?
A:The company recorded a $17.5 million noncash impairment expense in 2025 related to the chip line in the Korean fab. For 2026, they anticipate minor cash expenses for efficiency steps, which are not expected to be significant. The Korean fab, built during COVID, will be converted into an R&D center for ceramic tubes and potentially other products.
Q:When will we see the inflection point to reach the $35 million guidance for 2026?
A:The company expects most of the growth to occur in the second half of 2026. Agreements signed recently will lead to onboarding and ramp-up, with revenues shifting more towards CapEx rather than MSaaS.
Q:For 2026, should we expect low double-digit growth for teleradiology services?
A:Management did not provide specific guidance for teleradiology services but indicated that the assumption of low double-digit growth is "not far from real."
Q:How should we think about spending trends going forward, especially after the elevated Q4 spending?
A:The Q4 spending increase was due to seasonal factors like audit expenses, year-end items, and costs related to the VasoHealthcare acquisition. Sales and marketing expenses increased due to U.S. commercialization efforts. Future spending will depend on participation in events like the RSNA conference.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for teleradiology services growth in 2026, only stating that the assumption of low double-digit growth is "not far from real."
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI software
ARC system
Cedars Sinai
Congress Radiology
ECR
Korea
Nanox AI
Nanox ARC
Nanox Health
ability
approval
calcification
case
chip
confidence
distribution
emitter
environment
expansion
framework
image
impairment
initiative
lung
manufacturing facility
operation
plan manufacturing
priority
radiology conference
relationship
restructuring plan
screening
segment
semiconductor
software solution
solution update
system year
timing
tomosynthesis
NNOX Transcript
Nano-X Imaging Ltd. (NNOX) Q1 2026 Earnings Call Transcript
Neutral6-25
Nano-X Imaging Ltd. (NNOX) Q4 2025 Earnings Call Transcript
Unknown4-20
The earnings call reveals mixed signals: a 23% revenue increase is positive, but widening losses and weak margins are concerning. The optimistic guidance for 2026 and strategic acquisition of Nanox Health IT Inc. provide potential upside. However, the lack of clear guidance on teleradiology growth and increased expenses, particularly in sales and marketing, offset these positives. The Q&A highlights management's reluctance to provide detailed forecasts, adding uncertainty. With no significant catalysts or market cap details, the stock is likely to remain neutral, fluctuating between -2% and 2% over the next two weeks.
Nano-X Imaging Ltd. (NNOX) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call presents mixed signals. The company shows revenue growth and improved gross margins in teleradiology services, but faces challenges with AI solutions and a slight net loss increase. The Q&A section reveals unclear management responses, especially regarding system deployment, raising concerns. Despite optimistic guidance for future breakeven and revenue targets, the absence of immediate catalysts and some operational uncertainties suggest a neutral stock price movement over the next two weeks.
Nano-X Imaging Ltd. (NNOX) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture: slight revenue growth and strategic market expansion are positive, but increased losses and vague management responses in the Q&A section are concerning. The company's focus on AI and regulatory achievements offer long-term potential, but short-term financial metrics and execution risks temper optimism. With no clear guidance improvement, the stock is likely to remain stable in the near term.
NNOX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
